Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (greater than or equal to 12 to less than 18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (greater than or equal to 12 to less than 18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG-853 (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 21 Apr 2011 Status changed from not yet recruiting to discontinued.
    • 05 Aug 2010 Additional trial location [USA] identified as reported by ClinicalTrials.gov.
    • 11 Jun 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top